Biphasic Effect on Its Pharmacokinetics
Abstract
We studied changes in the pharmacokinetics of125I-recombinant human erythropoietin (125I-rh-EPO) after repeated subcutaneous administration once a week for 4 weeks. The plasma level of trichloroacetic acid-precipitable radioactivity after the fourth administration of125I-rh-EPO was minimal in 8 of 10 rats, whereas in the other two rats, the plasma level was almost the same or somewhat higher than that in control rats that had received the vehicle solution 3 times instead of the first three sequential administrations. Antibody against rh-EPO in serum was detected in all 10 rats receiving multiple administrations of 125I-rh-EPO. However, the binding capacity for 125I-rh-EPO in the latter two rats, assessed by an in vitro serum binding study, was lower than for the other eight rats, suggesting that the antibody level in these two was lower. The effect of intravenous preinjection of various volumes of anti-rh-EPO antiserum on the pharmacokinetics of125I-rh-EPO was examined. The half-life in the β-phase was prolonged at lower doses of antiserum. When the pretreatment dose of antiserum was further increased, the half-life in the β-phase rather shortened and the total body clearance (CLtotal) increased. These results suggest that repeated administration of rh-EPO induces the production of antibody against rh-EPO that affects the pharmacokinetics of rh-EPO in a biphasic manner; CLtotal was reduced when a small amount of antibody was produced, andCLtotal was increased when a large amount of antibody was produced.
Footnotes
-
Send reprint requests to: Dr. Yuichi Sugiyama, Professor and Chair, Faculty of Pharmaceutical Sciences, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113, Japan.
- Abbreviations used are::
- EPO
- erythropoietin
- rh-EPO
- recombinant human erythropoietin
- RME
- receptor-mediated endocytosis
- 125I-rh-EPO
- 125I-recombinant human erythropoietin
- BSA
- bovine serum albumin
- TCA
- trichloroacetic acid
- SD
- standard deviation
- AUC
- area under the plasma concentrationvs. time curve
- CLtotal
- total body clearance
- Bmax
- maximum binding capacity
- IgG
- immunoglobulin G
- t1/2β
- half-life in the β-phase
- Vc
- distribution volume of the central compartment
- rIFN-α2A
- recombinant interferon-α2A
- rIFN
- recombinant interferon
- rIL-2
- recombinant interleukin-2
- Received January 21, 1997.
- Accepted May 7, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|